Tubercular Drug Delivery Systems
Advances in Treatment of Infectious Diseases
Buch in deiner Nähe kaufen
Beschreibung
The disability-adjusted life year (DALY) is a generic measure of health effect that can
be used in cost-effectiveness analysis as an alternative to the quality-adjusted life year
(QALY). Infectious diseases are one of the major to cause significant losses of DALY and
QALY. Human infectious diseases are disorders that are triggered by the microorganisms
such as bacteria, fungi, viruses, or parasites. The majority of such diseases are contagiousand create a public health menace. There are several reasons why infectious diseases
are deadly diseases, and one of the primary reasons is the drug resistance developed
over time. Drug resistance-associated mutations are linked to increasing drug efflux,
modifications of the drugs, or their targets. Every year, new drugs are being approved by
FDA to treat infectious diseases. Nonetheless, the infectious diseases will undoubtedly
persist as permanent and main threats to humanity now and in the future, primarily
due to increased longevity that almost always comes at a cost of impaired immunity.
A total of four books are covered under the series of Infectious diseases.
• Malarial drug delivery systems• Tubercular drug delivery systems
• Viral drug delivery systems
• Infectious disease drug delivery systems
The theme of the second book is Tuberculosis (TB). This book addresses the recent
trends in drug delivery for treating TB using new formulation technologies, and the
mechanism how it can prevent or delay the drug resistance. It covers current drug therapy
and new drug targeting approaches focusing on innovative trend-defining technologies
and drug delivery platforms. It is essential to understand the relationship between host
pathogens for better treatment. Various novel and nano-formulations using promising
technologies are being explored to deliver TB drugs via different administration routesat right pathological site. This book addresses the gap between new and old treatment
TB modalities and how they are superior in pharmacological performance when tested
in in-vitro and in-vivo.
Audiences from a broad range of groups, from researchers, academicians, and public
health bodies to regulatory experts, can benefit from the compiled information to learnmore about patient needs and current research advances in the field of TB research.
The book targets new advances in areas of treatment and drug delivery sciences for tuberculosis. It covers advances in drug therapy and drug targeting that focus on innovative trend defining technologies and drug delivery platforms in the understanding of host-pathogens relationship for providing better therapy. A wide variety of novel and nano-formulations using promising technologies are being explored to deliver the drug via different administration routes. This book It addresses the gap between new approaches and old treatment modalities and how they are superior in pharmacological performance when tested in in-vitro and in-vivo. Audience from wide range group like from researchers to regulatory bodies can benefit from the compiled information to find out patient needs and current research advances in the field of tuberculosis research.
.
New advances in tuberculosis treatment, drug delivery, therapy and targeting Only publication with a roadmap for drug delivery that also covers clinical and medicinal aspects Covers nanoformulations and micro formulations
Autor*in
Ranjita Shegokar
Themen in »Tubercular Drug Delivery Systems«
Tuberculosis drug delievry nanoparticles in vivo drug targeting